You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameClopidogrel
Accession NumberDB00758  (APRD00444)
TypeSmall Molecule
GroupsApproved, Nutraceutical
DescriptionClopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to inhibit blood clots in a variety of conditions such as peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Clopidogrel is sold under the name Plavix by Sanofi and Bristol-Myers Squibb. The drug is an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor found on the membranes of platelet cells. Clopidogrel use is associated with several serious adverse drug reactions such as severe neutropenia, various forms of hemorrhage, and cardiovascular edema.
Structure
Thumb
Synonyms
(+)-Clopidogrel
Clopidogrelum
External Identifiers
  • SR-25990C
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Abbott-clopidogrelTablet75 mgOralAbbott Laboratories, Limited2014-03-172015-12-31Canada
Accel-clopidogrelTablet75 mgOralAccel Pharma Inc2014-09-042015-11-09Canada
Accel-clopidogrelTablet300 mgOralAccel Pharma IncNot applicableNot applicableCanada
Act ClopidogrelTablet75 mgOralActavis Pharma Company2011-12-07Not applicableCanada
Ag-clopidogrelTablet75 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Auro-clopidogrelTablet75 mgOralAuro Pharma Inc2014-02-06Not applicableCanada
Bio-clopidogrelTablet75 mgOralBiomed PharmaNot applicableNot applicableCanada
ClopidogrelTablet75 mgOralPro Doc Limitee2012-11-22Not applicableCanada
ClopidogrelTablet75 mgOralSivem Pharmaceuticals Ulc2012-06-11Not applicableCanada
ClopidogrelTablet75 mgOralSanis Health Inc2013-02-13Not applicableCanada
Clopidogrel ZentivaTablet, film coated75 mgOralSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaTablet, film coated75 mgOralSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaTablet, film coated75 mgOralSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaTablet, film coated75 mgOralSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaTablet, film coated75 mgOralSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaTablet, film coated300 mgOralSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaTablet, film coated75 mgOralSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaTablet, film coated75 mgOralSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaTablet, film coated75 mgOralSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaTablet, film coated75 mgOralSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaTablet, film coated300 mgOralSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaTablet, film coated75 mgOralSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaTablet, film coated75 mgOralSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaTablet, film coated300 mgOralSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaTablet, film coated75 mgOralSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaTablet, film coated75 mgOralSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaTablet, film coated75 mgOralSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaTablet, film coated300 mgOralSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaTablet, film coated75 mgOralSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaTablet, film coated75 mgOralSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaTablet, film coated75 mgOralSanofi Aventis2008-07-16Not applicableEu
Dom-clopidogrelTablet75 mgOralDominion Pharmacal2012-09-26Not applicableCanada
Ipg-clopidogrelTablet75 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-clopidogrelTablet300 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-clopidogrelTablet75 mgOralJamp Pharma Corporation2014-01-15Not applicableCanada
Mar-clopidogrelTablet300 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-clopidogrelTablet75 mgOralMarcan Pharmaceuticals Inc2015-01-21Not applicableCanada
Mint-clopidogrelTablet75 mgOralMint Pharmaceuticals Inc2013-07-18Not applicableCanada
Mint-clopidogrelTablet300 mgOralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mylan-clopidogrelTablet75 mgOralMylan Pharmaceuticals Ulc2011-12-07Not applicableCanada
Mylan-clopidogrelTablet300 mgOralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
PlavixTablet, film coated75 mg/1OralCardinal Health2007-09-20Not applicableUs
PlavixTablet, film coated75 mg/1OralSTAT Rx USA LLC1900-01-01Not applicableUs
PlavixTablet, film coated75 mg/1OralContract Pharmacy Services Pa1999-02-26Not applicableUs
PlavixTablet, film coated75 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
PlavixTablet, film coated300 mg/1OralBristol Myers Squibb/Sanofi Pharmaceuticals Partnership1900-01-01Not applicableUs
PlavixTablet, film coated300 mg/1OralCardinal Health1997-11-17Not applicableUs
PlavixTablet, film coated75 mg/1OralRebel Distributors Corp1900-01-01Not applicableUs
PlavixTablet75 mgOralSanofi Aventis Canada Inc1998-10-13Not applicableCanada
PlavixTablet, film coated75 mg/1OralA S Medication Solutions Llc1999-02-26Not applicableUs
PlavixTablet, film coated75 mg/1OralPd Rx Pharmaceuticals, Inc.1900-01-01Not applicableUs
PlavixTablet, film coated75 mg/1OralREMEDYREPACK INC.2013-03-192016-03-11Us
PlavixTablet, film coated75 mg/1OralPhysicians Total Care, Inc.2000-11-21Not applicableUs
PlavixTablet, film coated75 mg/1Oralbryant ranch prepack1900-01-01Not applicableUs
PlavixTablet, film coated75 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-13Not applicableUs
PlavixTablet, film coated75 mg/1OralBristol Myers Squibb/Sanofi Pharmaceuticals Partnership1900-01-01Not applicableUs
PlavixTablet300 mgOralSanofi Aventis Canada Inc2009-09-30Not applicableCanada
PMS-clopidogrelTablet75 mgOralPharmascience Inc2011-12-14Not applicableCanada
Priva-clopidogrelTablet75 mgOralPharmapar IncNot applicableNot applicableCanada
Q-clopidogrelTablet75 mgOralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Ran-clopidogrelTablet75 mgOralRanbaxy Pharmaceuticals Canada Inc.2012-04-30Not applicableCanada
Rbx-clopidogrelTablet75 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Riva ClopidogrelTablet75 mgOralLaboratoire Riva Inc2012-07-24Not applicableCanada
Sandoz ClopidogrelTablet75 mgOralSandoz Canada Incorporated2011-12-07Not applicableCanada
Teva-clopidogrelTablet300 mgOralTeva Canada Limited2013-01-02Not applicableCanada
Teva-clopidogrelTablet75 mgOralTeva Canada Limited2011-12-14Not applicableCanada
Torrent-clopidogrelTablet75 mgOralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-clopidogrelTablet300 mgOralApotex Inc2013-01-21Not applicableCanada
Apo-clopidogrelTablet75 mgOralApotex Inc2011-12-19Not applicableCanada
Clopidogre RatiopharmTablet, film coated75 mgOralTeva B.V.2015-02-19Not applicableEu
ClopidogrelTablet, film coated75 mg/1OralAccord Healthcare Inc.2013-05-15Not applicableUs
ClopidogrelTablet, film coated75 mg/1OralReady Meds2012-05-17Not applicableUs
ClopidogrelTablet, film coated75 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-05-17Not applicableUs
ClopidogrelTablet, film coated75 mg/1OralLegacy Pharmaceutical Packaging2012-05-172016-01-31Us
ClopidogrelTablet75 mg/1OralMacleods Pharmaceuticals Limited2012-10-16Not applicableUs
ClopidogrelTablet, film coated300 mg/1OralApotex Corp.2014-03-04Not applicableUs
ClopidogrelTablet75 mg/1OralUnit Dose Services2012-10-16Not applicableUs
ClopidogrelTablet, film coated75 mg/1OralCardinal Health2012-05-17Not applicableUs
ClopidogrelTablet, film coated75 mg/1OralMed Vantx, Inc.2012-05-17Not applicableUs
ClopidogrelTablet75 mg/1OralREMEDYREPACK INC.2015-04-29Not applicableUs
ClopidogrelTablet, film coated75 mg/1OralDIRECT RX2014-01-01Not applicableUs
ClopidogrelTablet, film coated75 mg/1OralAidarex Pharmaceuticals LLC2012-05-17Not applicableUs
ClopidogrelTablet, film coated75 mg/1OralCamber Pharmaceuticals, Inc.2015-06-18Not applicableUs
ClopidogrelTablet, film coated300 mg/1OralAccord Healthcare Inc.2013-05-15Not applicableUs
ClopidogrelTablet, film coated75 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-05-17Not applicableUs
ClopidogrelTablet, film coated75 mg/1OralWockhardt USA LLC.2012-05-22Not applicableUs
ClopidogrelTablet, film coated300 mg/1OralAmerican Health Packaging2012-11-282015-12-29Us
ClopidogrelTablet, film coated75 mg/1OralClinical Solutions Wholesale2012-05-17Not applicableUs
ClopidogrelTablet, film coated75 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
ClopidogrelTablet, film coated75 mg/1OralREMEDYREPACK INC.2016-11-03Not applicableUs
ClopidogrelTablet, film coated75 mg/1OralApotex Corp.2012-05-17Not applicableUs
ClopidogrelTablet75 mg/1OralPreferred Pharmaceuticals Inc.2016-10-18Not applicableUs
ClopidogrelTablet, film coated75 mg/1OralWockhardt Limited2012-05-22Not applicableUs
ClopidogrelTablet, film coated75 mg/1OralAmerican Health Packaging2014-03-14Not applicableUs
ClopidogrelTablet, film coated75 mg/1OralCitron Pharma LLC2012-05-17Not applicableUs
ClopidogrelTablet, film coated300 mg/1OralCamber Pharmaceuticals, Inc.2015-06-18Not applicableUs
ClopidogrelTablet75 mg/1OralVensun Pharmaceuticals, Inc.2014-11-01Not applicableUs
ClopidogrelTablet, film coated75 mg/1OralA S Medication Solutions2012-05-17Not applicableUs
ClopidogrelTablet, film coated300 mg/1OralWockhardt USA LLC.2012-11-13Not applicableUs
ClopidogrelTablet, film coated75 mg/1OralSt Marys Medical Park Pharmacy2014-04-21Not applicableUs
ClopidogrelTablet, film coated300 mg/1OralMajor Pharmaceuticals2015-04-06Not applicableUs
ClopidogrelTablet, film coated75 mg/1OralAmerican Health Packaging2012-06-142015-12-29Us
ClopidogrelTablet, film coated75 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
ClopidogrelTablet, film coated75 mg/1OralAurobindo Pharma Limited2012-05-17Not applicableUs
ClopidogrelTablet, film coated75 mg/1OralUnit Dose Services2012-05-17Not applicableUs
ClopidogrelTablet, film coated75 mg/1OralTeva Pharmaceuticals Usa, Inc.2012-05-17Not applicableUs
ClopidogrelTablet, film coated300 mg/1OralWockhardt Limited2012-11-13Not applicableUs
ClopidogrelTablet, film coated300 mg/1OralAmerican Health Packaging2014-03-28Not applicableUs
ClopidogrelTablet, film coated75 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
ClopidogrelTablet, film coated75 mg/1Oralbryant ranch prepack2012-05-17Not applicableUs
ClopidogrelTablet75 mg/1OralAmneal Pharmaceuticals of New York, LLC2013-09-30Not applicableUs
ClopidogrelTablet, film coated75 mg/1OralREMEDYREPACK INC.2013-05-06Not applicableUs
ClopidogrelTablet300 mg/1OralVensun Pharmaceuticals, Inc.2014-11-01Not applicableUs
ClopidogrelTablet, film coated75 mg/1OralProficient Rx LP2012-05-17Not applicableUs
ClopidogrelTablet, film coated75 mg/1OralREMEDYREPACK INC.2014-12-18Not applicableUs
ClopidogrelTablet, film coated75 mg/1OralInternational Laboratories, Inc.2013-12-02Not applicableUs
ClopidogrelTablet, film coated75 mg/1OralA S Medication Solutions2012-05-17Not applicableUs
ClopidogrelTablet, film coated75 mg/1OralApotex Corp.2012-05-17Not applicableUs
ClopidogrelTablet, film coated75 mg/1OralLegacy Pharmaceutical Packaging2012-05-17Not applicableUs
Clopidogrel AcinoTablet, film coated75 mgOralAcino Ag2009-07-28Not applicableEu
Clopidogrel AcinoTablet, film coated75 mgOralAcino Ag2009-07-28Not applicableEu
Clopidogrel AcinoTablet, film coated75 mgOralAcino Ag2009-07-28Not applicableEu
Clopidogrel AcinoTablet, film coated75 mgOralAcino Ag2009-07-28Not applicableEu
Clopidogrel AcinoTablet, film coated75 mgOralAcino Ag2009-07-28Not applicableEu
Clopidogrel AcinoTablet, film coated75 mgOralAcino Ag2009-07-28Not applicableEu
Clopidogrel AcinoTablet, film coated75 mgOralAcino Ag2009-07-28Not applicableEu
Clopidogrel BgrTablet, film coated75 mgOralBiogaran2009-09-21Not applicableEu
Clopidogrel BgrTablet, film coated75 mgOralBiogaran2009-09-21Not applicableEu
Clopidogrel BgrTablet, film coated75 mgOralBiogaran2009-09-21Not applicableEu
Clopidogrel BgrTablet, film coated75 mgOralBiogaran2009-09-21Not applicableEu
Clopidogrel BgrTablet, film coated75 mgOralBiogaran2009-09-21Not applicableEu
Clopidogrel BgrTablet, film coated75 mgOralBiogaran2009-09-21Not applicableEu
Clopidogrel BgrTablet, film coated75 mgOralBiogaran2009-09-21Not applicableEu
Clopidogrel BgrTablet, film coated75 mgOralBiogaran2009-09-21Not applicableEu
Clopidogrel BgrTablet, film coated75 mgOralBiogaran2009-09-21Not applicableEu
Clopidogrel BgrTablet, film coated75 mgOralBiogaran2009-09-21Not applicableEu
Clopidogrel BgrTablet, film coated75 mgOralBiogaran2009-09-21Not applicableEu
Clopidogrel BgrTablet, film coated75 mgOralBiogaran2009-09-21Not applicableEu
Clopidogrel BisulfateTablet, film coated300 mg/1OralBlenheim Pharmacal, Inc.2016-03-01Not applicableUs
Clopidogrel BisulfateTablet, film coated300 mg/1OralMylan Pharmaceuticals Inc.2012-05-17Not applicableUs
Clopidogrel BisulfateTablet75 mg/1OralCardinal Health2012-05-17Not applicableUs
Clopidogrel BisulfateTablet75 mg/1OralREMEDYREPACK INC.2013-02-182016-04-05Us
Clopidogrel BisulfateTablet, film coated300 mg/1OralMylan Institutional Inc.2012-05-17Not applicableUs
Clopidogrel BisulfateTablet, film coated75 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Clopidogrel BisulfateTablet, film coated75 mg/1OralREMEDYREPACK INC.2014-03-17Not applicableUs
Clopidogrel BisulfateTablet, film coated300 mg/1OralScie Gen Pharmaceuticals Inc2014-04-01Not applicableUs
Clopidogrel BisulfateTablet, film coated75 mg/1OralPhysicians Total Care, Inc.2012-05-25Not applicableUs
Clopidogrel BisulfateTablet75 mg/1OralREMEDYREPACK INC.2013-03-012016-04-05Us
Clopidogrel BisulfateTablet, film coated300 mg/1OralCardinal Health2012-05-17Not applicableUs
Clopidogrel BisulfateTablet75 mg/1OralMajor Pharmaceuticals2012-05-17Not applicableUs
Clopidogrel BisulfateTablet, film coated75 mg/1OralScie Gen Pharmaceuticals Inc2014-04-01Not applicableUs
Clopidogrel BisulfateTablet, film coated75 mg/1OralREMEDYREPACK INC.2014-06-03Not applicableUs
Clopidogrel BisulfateTablet, film coated75 mg/1OralCarilion Materials Management2012-05-17Not applicableUs
Clopidogrel BisulfateTablet, film coated75 mg/1OralDr.Reddy's Laboratories Limited2012-05-17Not applicableUs
Clopidogrel BisulfateTablet, film coated75 mg/1OralBlenheim Pharmacal, Inc.2014-02-14Not applicableUs
Clopidogrel BisulfateTablet75 mg/1OralPd Rx Pharmaceuticals, Inc.2012-05-17Not applicableUs
Clopidogrel BisulfateTablet, film coated75 mg/1OralREMEDYREPACK INC.2013-03-262016-04-05Us
Clopidogrel BisulfateTablet, film coated75 mg/1OralCardinal Health2012-06-08Not applicableUs
Clopidogrel BisulfateTablet, film coated300 mg/1OralGolden State Medical Supply, Inc.2014-09-15Not applicableUs
Clopidogrel BisulfateTablet, film coated75 mg/1OralProficient Rx LP2014-04-01Not applicableUs
Clopidogrel BisulfateTablet, film coated75 mg/1OralMylan Pharmaceuticals Inc.2012-05-17Not applicableUs
Clopidogrel BisulfateTablet, film coated75 mg/1OralPreferred Pharmaceuticals, Inc.2012-05-17Not applicableUs
Clopidogrel BisulfateTablet, film coated300 mg/1OralDr.Reddy's Laboratories Limited2012-05-17Not applicableUs
Clopidogrel BisulfateTablet75 mg/1OralREMEDYREPACK INC.2013-02-202016-10-13Us
Clopidogrel BisulfateTablet, film coated75 mg/1OralCardinal Health2012-05-17Not applicableUs
Clopidogrel BisulfateTablet, film coated75 mg/1OralSun Pharma Global FZE2012-05-18Not applicableUs
Clopidogrel BisulfateTablet75 mg/1OralTorrent Pharmaceuticals Limited2012-05-17Not applicableUs
Clopidogrel BisulfateTablet, film coated75 mg/1OralGolden State Medical Supply, Inc.2012-05-17Not applicableUs
Clopidogrel BisulfateTablet, film coated75 mg/1OralMylan Institutional Inc.2012-05-17Not applicableUs
Clopidogrel BisulfateTablet, film coated75 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Clopidogrel RatiopharmTablet, film coated75 mgOralTeva B.V.2015-02-19Not applicableEu
Clopidogrel RatiopharmTablet, film coated75 mgOralTeva B.V.2015-02-19Not applicableEu
Clopidogrel RatiopharmTablet, film coated75 mgOralTeva B.V.2015-02-19Not applicableEu
Clopidogrel RatiopharmTablet, film coated75 mgOralTeva B.V.2015-02-19Not applicableEu
Clopidogrel RatiopharmTablet, film coated75 mgOralTeva B.V.2015-02-19Not applicableEu
Clopidogrel RatiopharmTablet, film coated75 mgOralTeva B.V.2015-02-19Not applicableEu
Clopidogrel RatiopharmTablet, film coated75 mgOralTeva B.V.2015-02-19Not applicableEu
Clopidogrel RatiopharmTablet, film coated75 mgOralTeva B.V.2015-02-19Not applicableEu
Clopidogrel RatiopharmTablet, film coated75 mgOralTeva B.V.2015-02-19Not applicableEu
Clopidogrel RatiopharmTablet, film coated75 mgOralTeva B.V.2015-02-19Not applicableEu
Clopidogrel RatiopharmTablet, film coated75 mgOralTeva B.V.2015-02-19Not applicableEu
Clopidogrel RatiopharmTablet, film coated75 mgOralTeva B.V.2015-02-19Not applicableEu
Clopidogrel RatiopharmTablet, film coated75 mgOralTeva B.V.2015-02-19Not applicableEu
Clopidogrel RatiopharmTablet, film coated75 mgOralTeva B.V.2015-02-19Not applicableEu
Clopidogrel RatiopharmTablet, film coated75 mgOralTeva B.V.2015-02-19Not applicableEu
Clopidogrel RatiopharmTablet, film coated75 mgOralTeva B.V.2015-02-19Not applicableEu
Clopidogrel Ratiopharm GmbhTablet, film coated75 mgOralArchie Samuel S.R.O.2009-07-28Not applicableEu
Clopidogrel Ratiopharm GmbhTablet, film coated75 mgOralArchie Samuel S.R.O.2009-07-28Not applicableEu
Clopidogrel Ratiopharm GmbhTablet, film coated75 mgOralArchie Samuel S.R.O.2009-07-28Not applicableEu
Clopidogrel Ratiopharm GmbhTablet, film coated75 mgOralArchie Samuel S.R.O.2009-07-28Not applicableEu
Clopidogrel Ratiopharm GmbhTablet, film coated75 mgOralArchie Samuel S.R.O.2009-07-28Not applicableEu
Clopidogrel Ratiopharm GmbhTablet, film coated75 mgOralArchie Samuel S.R.O.2009-07-28Not applicableEu
Clopidogrel Ratiopharm GmbhTablet, film coated75 mgOralArchie Samuel S.R.O.2009-07-28Not applicableEu
Clopidogrel Ratiopharm GmbhTablet, film coated75 mgOralArchie Samuel S.R.O.2009-07-28Not applicableEu
Clopidogrel TevaTablet, film coated75 mgOralTeva Pharma B.V.2009-07-28Not applicableEu
Clopidogrel TevaTablet, film coated75 mgOralTeva Pharma B.V.2009-07-28Not applicableEu
Clopidogrel TevaTablet, film coated75 mgOralTeva Pharma B.V.2009-07-28Not applicableEu
Clopidogrel TevaTablet, film coated75 mgOralTeva Pharma B.V.2009-07-28Not applicableEu
Clopidogrel TevaTablet, film coated75 mgOralTeva Pharma B.V.2009-07-28Not applicableEu
Clopidogrel TevaTablet, film coated75 mgOralTeva Pharma B.V.2009-07-28Not applicableEu
Clopidogrel TevaTablet, film coated75 mgOralTeva Pharma B.V.2009-07-28Not applicableEu
Clopidogrel TevaTablet, film coated75 mgOralTeva Pharma B.V.2009-07-28Not applicableEu
Clopidogrel TevaTablet, film coated75 mgOralTeva Pharma B.V.2009-07-28Not applicableEu
Clopidogrel TevaTablet, film coated75 mgOralTeva Pharma B.V.2009-07-28Not applicableEu
Clopidogrel TevaTablet, film coated75 mgOralTeva Pharma B.V.2009-07-28Not applicableEu
Clopidogrel TevaTablet, film coated75 mgOralTeva Pharma B.V.2009-07-28Not applicableEu
Clopidogrel TevaTablet, film coated75 mgOralTeva Pharma B.V.2009-07-28Not applicableEu
Clopidogrel TevaTablet, film coated75 mgOralTeva Pharma B.V.2009-07-28Not applicableEu
Clopidogrel TevaTablet, film coated75 mgOralTeva Pharma B.V.2009-07-28Not applicableEu
Clopidogrel TevaTablet, film coated75 mgOralTeva Pharma B.V.2009-07-28Not applicableEu
Clopidogrel TevaTablet, film coated75 mgOralTeva Pharma B.V.2009-07-28Not applicableEu
ZylltTablet, film coated75 mgOralKrka, D.D., Novo Mesto2009-09-28Not applicableEu
ZylltTablet, film coated75 mgOralKrka, D.D., Novo Mesto2009-09-28Not applicableEu
ZylltTablet, film coated75 mgOralKrka, D.D., Novo Mesto2009-09-28Not applicableEu
ZylltTablet, film coated75 mgOralKrka, D.D., Novo Mesto2009-09-28Not applicableEu
ZylltTablet, film coated75 mgOralKrka, D.D., Novo Mesto2009-09-28Not applicableEu
ZylltTablet, film coated75 mgOralKrka, D.D., Novo Mesto2009-09-28Not applicableEu
ZylltTablet, film coated75 mgOralKrka, D.D., Novo Mesto2009-09-28Not applicableEu
ZylltTablet, film coated75 mgOralKrka, D.D., Novo Mesto2009-09-28Not applicableEu
ZylltTablet, film coated75 mgOralKrka, D.D., Novo Mesto2009-09-28Not applicableEu
ZylltTablet, film coated75 mgOralKrka, D.D., Novo Mesto2009-09-28Not applicableEu
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Clopido Grel 1a PharmaTablet, film coated75 mgOralAcino Pharma Gmb H  2009-07-28Not applicableEu
Clopidogrel 1a PharmaTablet, film coated75 mgOralAcino Pharma Gmb H  2009-07-28Not applicableEu
Clopidogrel 1a PharmaTablet, film coated75 mgOralAcino Pharma Gmb H  2009-07-28Not applicableEu
Clopidogrel 1a PharmaTablet, film coated75 mgOralAcino Pharma Gmb H  2009-07-28Not applicableEu
Clopidogrel 1a PharmaTablet, film coated75 mgOralAcino Pharma Gmb H  2009-07-28Not applicableEu
Clopidogrel 1a PharmaTablet, film coated75 mgOralAcino Pharma Gmb H  2009-07-28Not applicableEu
Clopidogrel 1a PharmaTablet, film coated75 mgOralAcino Pharma Gmb H  2009-07-28Not applicableEu
Clopidogrel Acino Pharma GmbhTablet, film coated75 mgOralAcino Pharma Gmb H2009-09-21Not applicableEu
Clopidogrel Acino Pharma GmbhTablet, film coated75 mgOralAcino Pharma Gmb H2009-09-21Not applicableEu
Clopidogrel Acino Pharma GmbhTablet, film coated75 mgOralAcino Pharma Gmb H2009-09-21Not applicableEu
Clopidogrel Acino Pharma GmbhTablet, film coated75 mgOralAcino Pharma Gmb H2009-09-21Not applicableEu
Clopidogrel Acino Pharma GmbhTablet, film coated75 mgOralAcino Pharma Gmb H2009-09-21Not applicableEu
Clopidogrel Acino Pharma GmbhTablet, film coated75 mgOralAcino Pharma Gmb H2009-09-21Not applicableEu
Clopidogrel Acino Pharma GmbhTablet, film coated75 mgOralAcino Pharma Gmb H2009-09-21Not applicableEu
Clopidogrel BmsTablet, film coated75 mgOralBristol Myers Squibb Pharma Eeig2008-07-16Not applicableEu
Clopidogrel BmsTablet, film coated75 mgOralBristol Myers Squibb Pharma Eeig2008-07-16Not applicableEu
Clopidogrel BmsTablet, film coated300 mgOralBristol Myers Squibb Pharma Eeig2008-07-16Not applicableEu
Clopidogrel BmsTablet, film coated75 mgOralBristol Myers Squibb Pharma Eeig2008-07-16Not applicableEu
Clopidogrel BmsTablet, film coated75 mgOralBristol Myers Squibb Pharma Eeig2008-07-16Not applicableEu
Clopidogrel BmsTablet, film coated75 mgOralBristol Myers Squibb Pharma Eeig2008-07-16Not applicableEu
Clopidogrel BmsTablet, film coated75 mgOralBristol Myers Squibb Pharma Eeig2008-07-16Not applicableEu
Clopidogrel BmsTablet, film coated75 mgOralBristol Myers Squibb Pharma Eeig2008-07-16Not applicableEu
Clopidogrel BmsTablet, film coated75 mgOralBristol Myers Squibb Pharma Eeig2008-07-16Not applicableEu
Clopidogrel BmsTablet, film coated75 mgOralBristol Myers Squibb Pharma Eeig2008-07-16Not applicableEu
Clopidogrel BmsTablet, film coated75 mgOralBristol Myers Squibb Pharma Eeig2008-07-16Not applicableEu
Clopidogrel BmsTablet, film coated75 mgOralBristol Myers Squibb Pharma Eeig2008-07-16Not applicableEu
Clopidogrel BmsTablet, film coated75 mgOralBristol Myers Squibb Pharma Eeig2008-07-16Not applicableEu
Clopidogrel BmsTablet, film coated300 mgOralBristol Myers Squibb Pharma Eeig2008-07-16Not applicableEu
Clopidogrel BmsTablet, film coated75 mgOralBristol Myers Squibb Pharma Eeig2008-07-16Not applicableEu
Clopidogrel BmsTablet, film coated75 mgOralBristol Myers Squibb Pharma Eeig2008-07-16Not applicableEu
Clopidogrel BmsTablet, film coated75 mgOralBristol Myers Squibb Pharma Eeig2008-07-16Not applicableEu
Clopidogrel BmsTablet, film coated300 mgOralBristol Myers Squibb Pharma Eeig2008-07-16Not applicableEu
Clopidogrel BmsTablet, film coated75 mgOralBristol Myers Squibb Pharma Eeig2008-07-16Not applicableEu
Clopidogrel HexalTablet, film coated75 mgOralAcino Pharma Gmb H2009-07-28Not applicableEu
Clopidogrel HexalTablet, film coated75 mgOralAcino Pharma Gmb H2009-07-28Not applicableEu
Clopidogrel HexalTablet, film coated75 mgOralAcino Pharma Gmb H2009-07-28Not applicableEu
Clopidogrel HexalTablet, film coated75 mgOralAcino Pharma Gmb H2009-07-28Not applicableEu
Clopidogrel HexalTablet, film coated75 mgOralAcino Pharma Gmb H2009-07-28Not applicableEu
Clopidogrel HexalTablet, film coated75 mgOralAcino Pharma Gmb H2009-07-28Not applicableEu
Clopidogrel HexalTablet, film coated75 mgOralAcino Pharma Gmb H2009-07-28Not applicableEu
Clopidogrel RatiopharmTablet, film coated75 mgOralArchie Samuel S.R.O.2009-09-23Not applicableEu
Clopidogrel RatiopharmTablet, film coated75 mgOralArchie Samuel S.R.O.2009-09-23Not applicableEu
Clopidogrel RatiopharmTablet, film coated75 mgOralArchie Samuel S.R.O.2009-09-23Not applicableEu
Clopidogrel RatiopharmTablet, film coated75 mgOralArchie Samuel S.R.O.2009-09-23Not applicableEu
Clopidogrel RatiopharmTablet, film coated75 mgOralArchie Samuel S.R.O.2009-09-23Not applicableEu
Clopidogrel RatiopharmTablet, film coated75 mgOralArchie Samuel S.R.O.2009-09-23Not applicableEu
Clopidogrel RatiopharmTablet, film coated75 mgOralArchie Samuel S.R.O.2009-09-23Not applicableEu
Clopidogrel RatiopharmTablet, film coated75 mgOralArchie Samuel S.R.O.2009-09-23Not applicableEu
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
DuoplavinSanofi Pharma Bristol Myers Squibb Snc
Salts
Name/CASStructureProperties
Clopidogrel Bisulfate
120202-66-6
Thumb
  • InChI Key: FDEODCTUSIWGLK-RSAXXLAASA-N
  • Monoisotopic Mass: 419.0264064
  • Average Mass: 419.9
DBSALT000029
Categories
UNIIA74586SNO7
CAS number113665-84-2
WeightAverage: 321.822
Monoisotopic: 321.059027158
Chemical FormulaC16H16ClNO2S
InChI KeyGKTWGGQPFAXNFI-HNNXBMFYSA-N
InChI
InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1
IUPAC Name
methyl (2S)-2-(2-chlorophenyl)-2-{4H,5H,6H,7H-thieno[3,2-c]pyridin-5-yl}acetate
SMILES
[H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl
Pharmacology
IndicationFor the reduction of atherosclerotic events (myocardial infarction, stroke, and vascular death) in patients with atherosclerosis documented by recent stroke, recent myocardial infarction, or established peripheral arterial disease.
Structured Indications
PharmacodynamicsSince clopidogrel is a prodrug, it must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation. This active metabolite selectively inhibits adenosine diphosphate (ADP) binding to its platelet P2Y12 receptor and subsequently the ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.
Mechanism of actionThe active metabolite of clopidogrel prevents binding of adenosine diphosphate (ADP) to its platelet receptor, impairing the ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. It is proposed that the inhibition involves a defect in the mobilization from the storage sites of the platelet granules to the outer membrane. he drug specifically and irreversibly inhibits the P2Y12 subtype of ADP receptor, which is important in aggregation of platelets and cross-linking by the protein fibrin. No direct interference occurs with the GPIIb/IIIa receptor. As the glycoprotein GPIIb/IIIa complex is the major receptor for fibrinogen, its impaired activation prevents fibrinogen binding to platelets and inhibits platelet aggregation. By blocking the amplification of platelet activation by released ADP, platelet aggregation induced by agonists other than ADP is also inhibited by the active metabolite of clopidogrel.
TargetKindPharmacological actionActionsOrganismUniProt ID
P2Y purinoceptor 12Proteinyes
antagonist
HumanQ9H244 details
Related Articles
AbsorptionAbsorption is at least 50% based on urinary excretion of clopidogrel-related metabolites. Bioavailability has not been found to be affected by food.
Volume of distributionNot Available
Protein binding98%
Metabolism

Hepatic, extensive and rapid, by hydrolysis to the main circulating metabolite, a carboxylic acid derivative, which accounts for approximately 85% of the circulating drug-related compounds. A glucuronic acid derivative of the carboxylic acid derivative has also been found in plasma and urine. Neither the parent compound nor the carboxylic acid derivative has a platelet inhibiting effect.

SubstrateEnzymesProduct
Clopidogrel
2-OxoclopidogrelDetails
2-Oxoclopidogrel
Not Available
Active Metabolite of ClopidogrelDetails
Clopidogrel
Not Available
Clopidogrel carboxylic acid derivativeDetails
Route of eliminationFollowing an oral dose of 14C-labeled clopidogrel in humans, approximately 50% of total radioactivity was excreted in urine and approximately 46% in feces over the 5 days post-dosing.
Half lifeCarboxylic acid derivative: 8 hours (after single and multiple doses). Covalent binding to platelets has accounted for 2% of radiolabeled clopidogrel with a half-life of 11 days.
ClearanceNot Available
ToxicityA single dose of clopidogrel at 1500 or 2000 mg/kg was lethal to mice and rats, with 3000 mg/kg lethal to baboons. Symptoms included vomiting, breathing difficulty, hemorrhage, and prostration.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Clopidogrel Action PathwayDrug actionSMP00260
Clopidogrel Metabolism PathwayDrug metabolismSMP00610
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Cytochrome P450 2C9
Gene symbol: CYP2C9
UniProt: P11712
rs1057910 CYP2C9*1C AllelePoor drug metabolizer, lower dose requirements, higher risk for drug-drug interactions17900275
Cytochrome P450 2C19
Gene symbol: CYP2C19
UniProt: P33261
rs4244285 CYP2C19*2A Allele, homozygotePoor drug metabolizer, lower dose requirements, higher risk for drug-drug interactions17900275
Cytochrome P450 2C19
Gene symbol: CYP2C19
UniProt: P33261
rs4244285 CYP2C19*2G > APatients are poor metabolizers of clopidogrel. More likely to experience poor cardiovascular outcomes.8195181
Cytochrome P450 2C19
Gene symbol: CYP2C19
UniProt: P33261
rs4244285 CYP2C19*2G > APatients are poor metabolizers of clopidogrel. More likely to experience poor cardiovascular outcomes.19706858
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbciximabClopidogrel may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Abiraterone resulting in a loss in efficacy.Approved
AcenocoumarolClopidogrel may increase the anticoagulant activities of Acenocoumarol.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Clopidogrel.Approved
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Clopidogrel.Approved, Vet Approved
AfatinibThe serum concentration of Clopidogrel can be increased when it is combined with Afatinib.Approved
AlbendazoleThe serum concentration of Clopidogrel can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Clopidogrel can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Clopidogrel can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Clopidogrel can be increased when it is combined with Alfentanil.Approved, Illicit
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Clopidogrel.Approved, Investigational
AlprostadilAlprostadil may increase the anticoagulant activities of Clopidogrel.Approved, Investigational
AlteplaseClopidogrel may increase the anticoagulant activities of Alteplase.Approved
ALX-0081Clopidogrel may increase the anticoagulant activities of ALX-0081.Investigational
AmantadineThe serum concentration of Clopidogrel can be increased when it is combined with Amantadine.Approved
Aminohippuric acidThe serum concentration of Clopidogrel can be increased when it is combined with Aminohippuric acid.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Clopidogrel.Approved, Withdrawn
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Aminosalicylic Acid.Approved
AmiodaroneThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Amiodarone resulting in a loss in efficacy.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Clopidogrel.Approved
AmlodipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Amlodipine.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Clopidogrel.Approved
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Clopidogrel.Approved
AmrinoneThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Amrinone.Approved
AmsacrineThe serum concentration of Clopidogrel can be increased when it is combined with Amsacrine.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Clopidogrel.Approved
AncrodClopidogrel may increase the anticoagulant activities of Ancrod.Investigational
AnistreplaseClopidogrel may increase the anticoagulant activities of Anistreplase.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Clopidogrel.Approved
Antithrombin III humanClopidogrel may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Apixaban.Approved
AprepitantThe serum concentration of Clopidogrel can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Aprotinin.Approved, Withdrawn
ArdeparinClopidogrel may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanClopidogrel may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArmodafinilThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Armodafinil resulting in a loss in efficacy.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Clopidogrel.Approved
AstaxanthinClopidogrel may increase the anticoagulant activities of Astaxanthin.Investigational
AstemizoleThe serum concentration of Clopidogrel can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe metabolism of Clopidogrel can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Clopidogrel can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Clopidogrel can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Clopidogrel.Approved
AzelastineThe metabolism of Azelastine can be decreased when combined with Clopidogrel.Approved
AzelnidipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Azelnidipine.Approved
AzimilideThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Azimilide.Investigational
AzithromycinThe serum concentration of Clopidogrel can be increased when it is combined with Azithromycin.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Balsalazide.Approved, Investigational
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Clopidogrel.Investigational
BarnidipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Barnidipine.Approved
BatroxobinClopidogrel may increase the anticoagulant activities of Batroxobin.Experimental
BecaplerminClopidogrel may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BemiparinClopidogrel may increase the anticoagulant activities of Bemiparin.Approved
BenidipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Benidipine.Approved
BenzocaineThe serum concentration of Clopidogrel can be increased when it is combined with Benzocaine.Approved
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Clopidogrel.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Clopidogrel.Approved
BepridilThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Bepridil.Approved, Withdrawn
BeraprostThe metabolism of Beraprost can be decreased when combined with Clopidogrel.Investigational
BexaroteneThe serum concentration of Clopidogrel can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe serum concentration of Clopidogrel can be increased when it is combined with Biperiden.Approved
BivalirudinClopidogrel may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Clopidogrel can be decreased when combined with Boceprevir.Approved
BortezomibThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Bortezomib resulting in a loss in efficacy.Approved, Investigational
BosentanThe serum concentration of Clopidogrel can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Clopidogrel can be increased when it is combined with Bosutinib.Approved
BromocriptineThe serum concentration of Clopidogrel can be increased when it is combined with Bromocriptine.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Clopidogrel.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Clopidogrel.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Bupropion can be increased when it is combined with Clopidogrel.Approved
BuspironeThe serum concentration of Clopidogrel can be increased when it is combined with Buspirone.Approved, Investigational
ButylphthalideButylphthalide may increase the anticoagulant activities of Clopidogrel.Investigational
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Clopidogrel.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Clopidogrel.Approved
CaiThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Cai.Investigational
CanagliflozinThe serum concentration of Clopidogrel can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Clopidogrel can be increased when it is combined with Candesartan.Approved
CangrelorCangrelor may decrease the antiplatelet activities of Clopidogrel.Approved
CapecitabineThe metabolism of Clopidogrel can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe serum concentration of Clopidogrel can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Clopidogrel can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Clopidogrel.Approved
CarvedilolThe serum concentration of Clopidogrel can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Clopidogrel can be increased when it is combined with Caspofungin.Approved
CeritinibThe serum concentration of Clopidogrel can be increased when it is combined with Ceritinib.Approved
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Clopidogrel.Withdrawn
CertoparinClopidogrel may increase the anticoagulant activities of Certoparin.Approved
ChloramphenicolThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Chloramphenicol resulting in a loss in efficacy.Approved, Vet Approved
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Clopidogrel.Approved, Vet Approved
ChlorpromazineThe serum concentration of Clopidogrel can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Clopidogrel can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Clopidogrel can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholecalciferolThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Cholecalciferol resulting in a loss in efficacy.Approved, Nutraceutical
CholesterolThe serum concentration of Clopidogrel can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Clopidogrel can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Clopidogrel can be increased when it is combined with Cilazapril.Approved
CilnidipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Cilnidipine.Approved
CilostazolClopidogrel may increase the anticoagulant activities of Cilostazol.Approved
CimetidineThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Cimetidine resulting in a loss in efficacy.Approved
CinnarizineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Cinnarizine.Approved
CiprofloxacinThe serum concentration of Clopidogrel can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Clopidogrel.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Citalopram resulting in a loss in efficacy.Approved
Citric AcidClopidogrel may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClarithromycinThe metabolism of Clopidogrel can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Clopidogrel can be decreased when combined with Clemastine.Approved
ClevidipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Clevidipine.Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Clopidogrel.Approved, Illicit
ClofazimineThe serum concentration of Clopidogrel can be increased when it is combined with Clofazimine.Approved, Investigational
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Clopidogrel.Investigational
ClomipramineThe serum concentration of Clopidogrel can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Clopidogrel.Approved, Illicit
ClotrimazoleThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Clotrimazole resulting in a loss in efficacy.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Clopidogrel.Approved
CobicistatThe metabolism of Clopidogrel can be decreased when combined with Cobicistat.Approved
ColchicineThe serum concentration of Clopidogrel can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Clopidogrel can be increased when it is combined with Colforsin.Experimental
CollagenaseThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Collagenase.Approved
ConivaptanThe serum concentration of Clopidogrel can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Clopidogrel can be decreased when combined with Crizotinib.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Clopidogrel.Approved, Investigational
CyclosporineThe metabolism of Clopidogrel can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Clopidogrel can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateClopidogrel may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Clopidogrel can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Clopidogrel can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Clopidogrel can be increased when it is combined with Dactinomycin.Approved
DalteparinClopidogrel may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidClopidogrel may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapsoneThe metabolism of Dapsone can be decreased when combined with Clopidogrel.Approved, Investigational
DarodipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Darodipine.Experimental
DarunavirThe metabolism of Clopidogrel can be decreased when combined with Darunavir.Approved
DasabuvirThe serum concentration of Dasabuvir can be increased when it is combined with Clopidogrel.Approved
DasatinibDasatinib may increase the anticoagulant activities of Clopidogrel.Approved, Investigational
DaunorubicinThe serum concentration of Clopidogrel can be decreased when it is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Clopidogrel can be decreased when it is combined with Deferasirox.Approved, Investigational
DefibrotideClopidogrel may increase the anticoagulant activities of Defibrotide.Approved, Investigational
DelavirdineThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Delavirdine resulting in a loss in efficacy.Approved
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Deoxycholic Acid.Approved
dersalazineThe risk or severity of adverse effects can be increased when Clopidogrel is combined with dersalazine.Investigational
DesipramineThe serum concentration of Clopidogrel can be increased when it is combined with Desipramine.Approved
DesirudinClopidogrel may increase the anticoagulant activities of Desirudin.Approved
DesloratadineThe serum concentration of Clopidogrel can be increased when it is combined with Desloratadine.Approved, Investigational
DesmoteplaseClopidogrel may increase the anticoagulant activities of Desmoteplase.Investigational
DexamethasoneThe serum concentration of Clopidogrel can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextranClopidogrel may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Clopidogrel may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Clopidogrel may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Clopidogrel may increase the anticoagulant activities of Dextran 75.Approved
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Clopidogrel.Approved
DiazepamThe metabolism of Diazepam can be decreased when combined with Clopidogrel.Approved, Illicit, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Clopidogrel.Approved, Vet Approved
DicoumarolClopidogrel may increase the anticoagulant activities of Dicoumarol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Diflunisal.Approved
DigoxinThe serum concentration of Clopidogrel can be decreased when it is combined with Digoxin.Approved
DihydroergotamineThe metabolism of Clopidogrel can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Diltiazem.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Clopidogrel.Approved
DipyridamoleThe serum concentration of Clopidogrel can be increased when it is combined with Dipyridamole.Approved
DitazoleClopidogrel may increase the anticoagulant activities of Ditazole.Approved, Withdrawn
DomperidoneThe metabolism of Domperidone can be decreased when combined with Clopidogrel.Approved, Investigational, Vet Approved
DotarizineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Dotarizine.Investigational
DoxazosinThe serum concentration of Clopidogrel can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Clopidogrel can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Clopidogrel can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Clopidogrel can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Clopidogrel can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Clopidogrel can be decreased when combined with Dronedarone.Approved
Drotrecogin alfaClopidogrel may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
Edetic AcidClopidogrel may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanClopidogrel may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Efavirenz resulting in a loss in efficacy.Approved, Investigational
EfonidipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Efonidipine.Approved
ElbasvirThe serum concentration of Clopidogrel can be increased when it is combined with Elbasvir.Approved
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Clopidogrel.Approved
EnalaprilThe serum concentration of Clopidogrel can be increased when it is combined with Enalapril.Approved, Vet Approved
EnoxaparinClopidogrel may increase the anticoagulant activities of Enoxaparin.Approved
EnzalutamideThe serum concentration of Enzalutamide can be increased when it is combined with Clopidogrel.Approved
EperisoneThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Eperisone.Approved, Investigational
EpinastineThe metabolism of Epinastine can be decreased when combined with Clopidogrel.Approved, Investigational
eplivanserineClopidogrel may increase the anticoagulant activities of eplivanserine.Investigational
EpoprostenolEpoprostenol may increase the antiplatelet activities of Clopidogrel.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Clopidogrel.Approved, Investigational
ErgonovineThe serum concentration of Clopidogrel can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Clopidogrel can be increased when it is combined with Ergotamine.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Clopidogrel.Approved, Investigational
ErythromycinErythromycin may decrease the antiplatelet activities of Clopidogrel.Approved, Vet Approved
ErythromycinThe metabolism of Clopidogrel can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Eslicarbazepine acetate resulting in a loss in efficacy.Approved
EsomeprazoleEsomeprazole may decrease the antiplatelet activities of Clopidogrel.Approved, Investigational
EstradiolThe metabolism of Estradiol can be decreased when combined with Clopidogrel.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Clopidogrel can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Clopidogrel can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Clopidogrel can be decreased when it is combined with Estrone.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Clopidogrel.Approved
Ethyl biscoumacetateClopidogrel may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Clopidogrel.Approved, Illicit
EtoposideThe serum concentration of Clopidogrel can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Etravirine resulting in a loss in efficacy.Approved
FelodipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Felodipine.Approved, Investigational
FendilineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Fendiline.Withdrawn
FentanylThe serum concentration of Clopidogrel can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Clopidogrel can be increased when it is combined with Fexofenadine.Approved
FibrinolysinClopidogrel may increase the anticoagulant activities of Fibrinolysin.Approved
FidaxomicinThe serum concentration of Clopidogrel can be increased when it is combined with Fidaxomicin.Approved
FloxuridineThe metabolism of Clopidogrel can be decreased when combined with Floxuridine.Approved
FluconazoleThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Fluconazole resulting in a loss in efficacy.Approved
FluindioneClopidogrel may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Flunarizine.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Clopidogrel.Approved, Illicit
FluorouracilThe metabolism of Clopidogrel can be decreased when combined with Fluorouracil.Approved
FluoxetineThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Fluoxetine resulting in a loss in efficacy.Approved, Vet Approved
FlupentixolThe serum concentration of Clopidogrel can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Clopidogrel can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Clopidogrel can be increased when it is combined with Flurazepam.Approved, Illicit
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Clopidogrel.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Clopidogrel.Approved, Investigational
FondaparinuxClopidogrel may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumClopidogrel may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FosamprenavirThe metabolism of Clopidogrel can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Clopidogrel can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Clopidogrel can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Clopidogrel can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Gabapentin.Approved, Investigational
GabexateClopidogrel may increase the anticoagulant activities of Gabexate.Investigational
GallopamilThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Gallopamil.Investigational
GefitinibThe serum concentration of Clopidogrel can be increased when it is combined with Gefitinib.Approved, Investigational
GemfibrozilThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Gemfibrozil resulting in a loss in efficacy.Approved
GenisteinThe serum concentration of Clopidogrel can be increased when it is combined with Genistein.Investigational
GlucosamineGlucosamine may increase the antiplatelet activities of Clopidogrel.Approved
GlyburideThe serum concentration of Clopidogrel can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Clopidogrel can be increased when it is combined with Glycerol.Experimental
Gramicidin DThe serum concentration of Clopidogrel can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe serum concentration of Clopidogrel can be increased when it is combined with Grepafloxacin.Withdrawn
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Clopidogrel.Approved
HaloperidolThe serum concentration of Clopidogrel can be increased when it is combined with Haloperidol.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Clopidogrel.Approved, Vet Approved
HeparinClopidogrel may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineClopidogrel may increase the anticoagulant activities of Higenamine.Investigational
HirulogClopidogrel may increase the anticoagulant activities of Hirulog.Experimental
HydrocortisoneThe serum concentration of Clopidogrel can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Clopidogrel.Approved
IbudilastIbudilast may increase the anticoagulant activities of Clopidogrel.Approved, Investigational
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Clopidogrel.Approved
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Clopidogrel.Approved, Nutraceutical
IdelalisibThe serum concentration of Clopidogrel can be increased when it is combined with Idelalisib.Approved
idraparinuxClopidogrel may increase the anticoagulant activities of idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Clopidogrel.Approved, Withdrawn
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Clopidogrel.Approved
IloprostIloprost may increase the antiplatelet activities of Clopidogrel.Approved, Investigational
ImatinibThe metabolism of Clopidogrel can be decreased when combined with Imatinib.Approved
ImipramineThe serum concentration of Clopidogrel can be increased when it is combined with Imipramine.Approved
IndinavirThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Indinavir resulting in a loss in efficacy.Approved
IndobufenClopidogrel may increase the anticoagulant activities of Indobufen.Investigational
IndomethacinThe serum concentration of Clopidogrel can be increased when it is combined with Indomethacin.Approved, Investigational
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Clopidogrel.Approved, Investigational
IrinotecanThe metabolism of Irinotecan can be decreased when combined with Clopidogrel.Approved, Investigational
IsavuconazoniumThe metabolism of Clopidogrel can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe metabolism of Isoflurane can be decreased when combined with Clopidogrel.Approved, Vet Approved
IsoniazidThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Isoniazid resulting in a loss in efficacy.Approved
IsradipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Isradipine.Approved
ItraconazoleThe metabolism of Clopidogrel can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Clopidogrel can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Clopidogrel can be increased when it is combined with Ivermectin.Approved, Vet Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Clopidogrel.Approved
Kct 0809Clopidogrel may increase the anticoagulant activities of Kct 0809.Investigational
KetamineThe metabolism of Ketamine can be decreased when combined with Clopidogrel.Approved, Vet Approved
KetanserinKetanserin may increase the anticoagulant activities of Clopidogrel.Investigational
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Clopidogrel.Approved
KetoconazoleThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Ketoconazole resulting in a loss in efficacy.Approved, Investigational
LacidipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Lacidipine.Approved
LamotrigineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Lamotrigine.Approved, Investigational
LansoprazoleThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Lansoprazole resulting in a loss in efficacy.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Clopidogrel.Approved, Investigational
LeflunomideThe metabolism of Clopidogrel can be decreased when combined with Leflunomide.Approved, Investigational
LepirudinClopidogrel may increase the anticoagulant activities of Lepirudin.Approved
LercanidipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Lercanidipine.Approved, Investigational
LevofloxacinThe serum concentration of Clopidogrel can be increased when it is combined with Levofloxacin.Approved, Investigational
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Clopidogrel.Approved
LevothyroxineThe serum concentration of Clopidogrel can be decreased when it is combined with Levothyroxine.Approved
LicofeloneThe metabolism of Licofelone can be decreased when combined with Clopidogrel.Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Clopidogrel.Approved, Vet Approved
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Clopidogrel.Approved
LiothyronineThe serum concentration of Clopidogrel can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Clopidogrel can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Clopidogrel can be increased when it is combined with Lisinopril.Approved, Investigational
LomitapideThe serum concentration of Clopidogrel can be increased when it is combined with Lomitapide.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Clopidogrel.Approved
LopinavirThe metabolism of Clopidogrel can be decreased when combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Clopidogrel.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Clopidogrel.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Clopidogrel.Approved
LovastatinThe metabolism of Clopidogrel can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Luliconazole resulting in a loss in efficacy.Approved
LumacaftorThe serum concentration of Clopidogrel can be decreased when it is combined with Lumacaftor.Approved
Magnesium SulfateThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Magnesium Sulfate.Approved, Vet Approved
MalathionThe metabolism of Malathion can be decreased when combined with Clopidogrel.Approved, Investigational
ManidipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Manidipine.Approved
MaprotilineThe serum concentration of Clopidogrel can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Clopidogrel can be increased when it is combined with Mebendazole.Approved, Vet Approved
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Clopidogrel.Approved
MefloquineThe serum concentration of Clopidogrel can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Clopidogrel can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Clopidogrel.Approved, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Clopidogrel.Investigational, Withdrawn
MeprobamateThe serum concentration of Clopidogrel can be increased when it is combined with Meprobamate.Approved, Illicit
MesalazineThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Mesalazine.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Clopidogrel.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Clopidogrel.Approved, Vet Approved
MethylphenobarbitalThe metabolism of Methylphenobarbital can be decreased when combined with Clopidogrel.Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Clopidogrel.Approved
MetoprololThe serum concentration of Clopidogrel can be increased when it is combined with Metoprolol.Approved, Investigational
MexiletineThe metabolism of Clopidogrel can be decreased when combined with Mexiletine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Clopidogrel.Approved
MibefradilThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Clopidogrel can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Clopidogrel can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Clopidogrel can be increased when it is combined with Mifepristone.Approved, Investigational
MilrinoneMilrinone may increase the anticoagulant activities of Clopidogrel.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Clopidogrel.Approved
MitomycinThe serum concentration of Clopidogrel can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Clopidogrel can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Clopidogrel can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MoclobemideThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Moclobemide resulting in a loss in efficacy.Approved
ModafinilThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Modafinil resulting in a loss in efficacy.Approved, Investigational
MorphineMorphine may decrease the antiplatelet activities of Clopidogrel.Approved, Investigational
MorphineThe metabolism of Morphine can be decreased when combined with Clopidogrel.Approved, Investigational
muraglitazarThe metabolism of muraglitazar can be decreased when combined with Clopidogrel.Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Clopidogrel.Approved, Investigational
NadroparinClopidogrel may increase the anticoagulant activities of Nadroparin.Approved
NafamostatClopidogrel may increase the anticoagulant activities of Nafamostat.Investigational
NafcillinThe serum concentration of Clopidogrel can be decreased when it is combined with Nafcillin.Approved
NaftopidilThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Naftopidil.Investigational
NaloxoneThe metabolism of Naloxone can be decreased when combined with Clopidogrel.Approved, Vet Approved
NaltrexoneThe serum concentration of Clopidogrel can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Clopidogrel.Approved, Vet Approved
NaringeninThe serum concentration of Clopidogrel can be increased when it is combined with Naringenin.Experimental
NCX 4016The risk or severity of adverse effects can be increased when Clopidogrel is combined with NCX 4016.Investigational
NefazodoneThe metabolism of Clopidogrel can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Nelfinavir resulting in a loss in efficacy.Approved
NeostigmineThe serum concentration of Clopidogrel can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Clopidogrel can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Clopidogrel can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Nicardipine resulting in a loss in efficacy.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Clopidogrel.Approved
NifedipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nifedipine.Approved
NiguldipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Niguldipine.Experimental
NilotinibThe metabolism of Clopidogrel can be decreased when combined with Nilotinib.Approved, Investigational
NiludipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Niludipine.Experimental
NilvadipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nilvadipine.Approved
NimesulideThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nimesulide.Approved, Withdrawn
NimodipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nimodipine.Approved
NisoldipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nisoldipine.Approved
NitrazepamThe serum concentration of Clopidogrel can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nitrendipine.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Nitroaspirin.Investigational
NorethisteroneThe serum concentration of Clopidogrel can be decreased when it is combined with Norethisterone.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Obinutuzumab.Approved
OlaparibThe metabolism of Clopidogrel can be decreased when combined with Olaparib.Approved
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Clopidogrel.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Olsalazine.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Clopidogrel.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Clopidogrel.Approved
OmeprazoleOmeprazole may decrease the antiplatelet activities of Clopidogrel.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Clopidogrel can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Clopidogrel.Approved
OtamixabanClopidogrel may increase the anticoagulant activities of Otamixaban.Investigational
P-NitrophenolThe serum concentration of Clopidogrel can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Clopidogrel.Approved, Vet Approved
PalbociclibThe serum concentration of Clopidogrel can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Clopidogrel can be increased when it is combined with Palmitic Acid.Experimental
PantoprazoleThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Pantoprazole resulting in a loss in efficacy.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Clopidogrel.Approved
ParitaprevirThe serum concentration of Paritaprevir can be increased when it is combined with Clopidogrel.Approved
ParnaparinClopidogrel may increase the anticoagulant activities of Parnaparin.Approved
ParoxetineThe serum concentration of Clopidogrel can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe metabolism of Pazopanib can be decreased when combined with Clopidogrel.Approved
Peginterferon alfa-2bThe serum concentration of Clopidogrel can be increased when it is combined with Peginterferon alfa-2b.Approved
PentamidineThe metabolism of Pentamidine can be decreased when combined with Clopidogrel.Approved
PentobarbitalThe metabolism of Clopidogrel can be increased when combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Clopidogrel.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Clopidogrel.Approved, Investigational
PerhexilineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Perhexiline.Approved
PerindoprilThe serum concentration of Clopidogrel can be increased when it is combined with Perindopril.Approved
PermethrinThe metabolism of Permethrin can be decreased when combined with Clopidogrel.Approved, Investigational
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Clopidogrel.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Clopidogrel.Approved
PhenindioneClopidogrel may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Clopidogrel can be increased when combined with Phenobarbital.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Clopidogrel.Approved
PhenytoinThe metabolism of Clopidogrel can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe serum concentration of Clopidogrel can be increased when it is combined with Pimozide.Approved
PinaveriumThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Pinaverium.Approved
PioglitazoneThe serum concentration of Pioglitazone can be increased when it is combined with Clopidogrel.Approved, Investigational
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Clopidogrel.Approved, Investigational
PitavastatinThe metabolism of Pitavastatin can be decreased when combined with Clopidogrel.Approved
PlasminClopidogrel may increase the anticoagulant activities of Plasmin.Investigational
Platelet Activating FactorThe serum concentration of Clopidogrel can be decreased when it is combined with Platelet Activating Factor.Experimental
PonatinibThe metabolism of Ponatinib can be decreased when combined with Clopidogrel.Approved
PosaconazoleThe metabolism of Clopidogrel can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Clopidogrel.Approved
PravastatinThe serum concentration of Clopidogrel can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Clopidogrel can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Clopidogrel can be increased when it is combined with Prednisone.Approved, Vet Approved
PregabalinThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrenylamineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Prenylamine.Withdrawn
PrimidoneThe metabolism of Clopidogrel can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Clopidogrel can be increased when it is combined with Probenecid.Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Clopidogrel.Approved, Vet Approved
PromethazineThe serum concentration of Clopidogrel can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Clopidogrel can be increased when it is combined with Propafenone.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Clopidogrel.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Clopidogrel can be increased when it is combined with Propranolol.Approved, Investigational
Protein CClopidogrel may increase the anticoagulant activities of Protein C.Approved
Protein S humanClopidogrel may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeClopidogrel may increase the anticoagulant activities of Protocatechualdehyde.Approved
ProtriptylineThe serum concentration of Clopidogrel can be increased when it is combined with Protriptyline.Approved
PyrimethamineThe metabolism of Clopidogrel can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe serum concentration of Clopidogrel can be increased when it is combined with Quazepam.Approved, Illicit
QuercetinThe serum concentration of Clopidogrel can be increased when it is combined with Quercetin.Experimental
QuinacrineThe serum concentration of Clopidogrel can be increased when it is combined with Quinacrine.Approved
QuinidineThe metabolism of Quinidine can be decreased when combined with Clopidogrel.Approved
QuinineThe metabolism of Quinine can be decreased when combined with Clopidogrel.Approved
RabeprazoleThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Rabeprazole resulting in a loss in efficacy.Approved, Investigational
RamatrobanRamatroban may increase the anticoagulant activities of Clopidogrel.Investigational
RanitidineThe serum concentration of Clopidogrel can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Clopidogrel can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Clopidogrel can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Clopidogrel can be increased when it is combined with Regorafenib.Approved
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Clopidogrel.Approved, Investigational
ReserpineThe serum concentration of Clopidogrel can be decreased when it is combined with Reserpine.Approved
ResveratrolResveratrol may increase the anticoagulant activities of Clopidogrel.Experimental, Investigational
ReteplaseClopidogrel may increase the anticoagulant activities of Reteplase.Approved
ReviparinClopidogrel may increase the anticoagulant activities of Reviparin.Approved
RidogrelRidogrel may increase the anticoagulant activities of Clopidogrel.Approved
RifabutinThe risk or severity of adverse effects can be increased when Rifabutin is combined with Clopidogrel.Approved
RifampicinThe risk or severity of adverse effects can be increased when Rifampicin is combined with Clopidogrel.Approved
RifapentineThe risk or severity of adverse effects can be increased when Rifapentine is combined with Clopidogrel.Approved
RilpivirineThe serum concentration of Clopidogrel can be increased when it is combined with Rilpivirine.Approved
RiociguatThe metabolism of Riociguat can be decreased when combined with Clopidogrel.Approved
RisedronateThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Risedronate.Approved, Investigational
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Clopidogrel.Approved, Investigational
RivaroxabanClopidogrel may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Clopidogrel.Investigational, Withdrawn
RolapitantThe serum concentration of Clopidogrel can be increased when it is combined with Rolapitant.Approved
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Clopidogrel.Approved, Investigational
RopiniroleThe metabolism of Clopidogrel can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Clopidogrel.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Clopidogrel.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Clopidogrel.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Salicylic acid.Approved, Vet Approved
SaquinavirThe metabolism of Clopidogrel can be decreased when combined with Saquinavir.Approved, Investigational
SCH-530348SCH-530348 may increase the anticoagulant activities of Clopidogrel.Investigational
ScopolamineThe serum concentration of Clopidogrel can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Clopidogrel can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Clopidogrel.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Clopidogrel.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Clopidogrel.Approved, Investigational
SertralineThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Sertraline resulting in a loss in efficacy.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Clopidogrel.Approved, Vet Approved
SildenafilThe metabolism of Clopidogrel can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Clopidogrel can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Clopidogrel can be increased when it is combined with Simeprevir.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Clopidogrel.Approved
SirolimusThe serum concentration of Clopidogrel can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Clopidogrel.Approved, Investigational
SorafenibThe metabolism of Sorafenib can be decreased when combined with Clopidogrel.Approved, Investigational
SpironolactoneThe serum concentration of Clopidogrel can be increased when it is combined with Spironolactone.Approved
SRT501SRT501 may increase the anticoagulant activities of Clopidogrel.Investigational
St. John's WortThe serum concentration of Clopidogrel can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Clopidogrel can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Clopidogrel can be increased when it is combined with Stiripentol.Approved
StreptokinaseClopidogrel may increase the anticoagulant activities of Streptokinase.Approved
StreptozocinThe serum concentration of Clopidogrel can be decreased when it is combined with Streptozocin.Approved
SulfadiazineThe metabolism of Clopidogrel can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Clopidogrel can be decreased when combined with Sulfamethoxazole.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Clopidogrel.Approved
SulfisoxazoleThe metabolism of Clopidogrel can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulodexideClopidogrel may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SumatriptanThe serum concentration of Clopidogrel can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Clopidogrel can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Clopidogrel can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Clopidogrel can be decreased when it is combined with Tacrolimus.Approved, Investigational
TAK-390MRThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with TAK-390MR resulting in a loss in efficacy.Investigational
TamoxifenThe serum concentration of Clopidogrel can be decreased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Clopidogrel can be increased when it is combined with Taurocholic Acid.Experimental
TazaroteneThe metabolism of Tazarotene can be decreased when combined with Clopidogrel.Approved, Investigational
TelaprevirThe metabolism of Clopidogrel can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Clopidogrel can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Clopidogrel can be increased when it is combined with Telmisartan.Approved, Investigational
TemazepamThe metabolism of Temazepam can be decreased when combined with Clopidogrel.Approved
TemsirolimusThe serum concentration of Clopidogrel can be increased when it is combined with Temsirolimus.Approved
TenecteplaseClopidogrel may increase the anticoagulant activities of Tenecteplase.Approved
TenofovirThe metabolism of Clopidogrel can be decreased when combined with Tenofovir.Approved, Investigational
TerazosinThe serum concentration of Clopidogrel can be increased when it is combined with Terazosin.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Clopidogrel.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Clopidogrel can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Clopidogrel can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Clopidogrel can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Clopidogrel.Approved, Investigational
TheophyllineThe metabolism of Theophylline can be decreased when combined with Clopidogrel.Approved
ThiotepaThe metabolism of Clopidogrel can be decreased when combined with Thiotepa.Approved
TicagrelorThe serum concentration of Clopidogrel can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Ticlopidine resulting in a loss in efficacy.Approved
TinzaparinClopidogrel may increase the anticoagulant activities of Tinzaparin.Approved
TipranavirTipranavir may increase the antiplatelet activities of Clopidogrel.Approved, Investigational
TirofibanClopidogrel may increase the anticoagulant activities of Tirofiban.Approved
TocilizumabThe serum concentration of Clopidogrel can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Clopidogrel can be decreased when combined with Tolbutamide.Approved
Tolfenamic AcidThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Tolfenamic Acid.Approved
TolvaptanThe serum concentration of Clopidogrel can be increased when it is combined with Tolvaptan.Approved
TopiramateThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Topiramate resulting in a loss in efficacy.Approved
TorasemideThe metabolism of Torasemide can be decreased when combined with Clopidogrel.Approved
TositumomabThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Tositumomab.Approved
TramadolThe metabolism of Tramadol can be decreased when combined with Clopidogrel.Approved, Investigational
TranilastThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Tranilast.Approved, Investigational
TranylcypromineThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Tranylcypromine resulting in a loss in efficacy.Approved
TrapidilTrapidil may increase the anticoagulant activities of Clopidogrel.Approved
TrazodoneThe serum concentration of Clopidogrel can be decreased when it is combined with Trazodone.Approved, Investigational
TreprostinilThe serum concentration of Treprostinil can be increased when it is combined with Clopidogrel.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Clopidogrel.Approved, Investigational, Nutraceutical
TrifluoperazineThe serum concentration of Clopidogrel can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Clopidogrel can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TriflusalClopidogrel may increase the anticoagulant activities of Triflusal.Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Clopidogrel.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Clopidogrel.Approved, Vet Approved
TrimipramineThe serum concentration of Clopidogrel can be increased when it is combined with Trimipramine.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Clopidogrel.Withdrawn
TroleandomycinThe serum concentration of Clopidogrel can be increased when it is combined with Troleandomycin.Approved
UrokinaseClopidogrel may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
Valproic AcidThe metabolism of Clopidogrel can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Clopidogrel can be decreased when combined with Valsartan.Approved, Investigational
VemurafenibThe serum concentration of Clopidogrel can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Clopidogrel can be decreased when combined with Venlafaxine.Approved
VerapamilThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Verapamil.Approved
VinblastineThe serum concentration of Clopidogrel can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Clopidogrel can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Clopidogrel can be increased when it is combined with Vinorelbine.Approved, Investigational
VinpocetineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Vinpocetine.Investigational
Vitamin EVitamin E may increase the antiplatelet activities of Clopidogrel.Approved, Nutraceutical, Vet Approved
VorapaxarClopidogrel may increase the anticoagulant activities of Vorapaxar.Approved
VoriconazoleThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Voriconazole resulting in a loss in efficacy.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Clopidogrel.Approved
WarfarinClopidogrel may increase the anticoagulant activities of Warfarin.Approved
XimelagatranClopidogrel may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
XylometazolineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Xylometazoline.Approved
Ym150Clopidogrel may increase the anticoagulant activities of Ym150.Investigational
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Clopidogrel.Approved, Investigational
ZiconotideThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Ziconotide.Approved
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Clopidogrel.Approved
ZimelidineThe serum concentration of Clopidogrel can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Clopidogrel can be decreased when combined with Ziprasidone.Approved
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Clopidogrel.Approved
Food InteractionsNot Available
References
Synthesis Reference

Revital Lifshitz-Liron, “Novel crystal forms III, IV, V, and novel amorphous form of clopidogrel hydrogensulfate, processes for their preparation, processes for the preparation of form I, compositions containing the new forms and methods of administering the new forms.” U.S. Patent US20030114479, issued June 19, 2003.

US20030114479
General References
  1. Chan FK, Ching JY, Hung LC, Wong VW, Leung VK, Kung NN, Hui AJ, Wu JC, Leung WK, Lee VW, Lee KK, Lee YT, Lau JY, To KF, Chan HL, Chung SC, Sung JJ: Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med. 2005 Jan 20;352(3):238-44. [PubMed:15659723 ]
  2. Perry CG, Shuldiner AR: Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation? J Hum Genet. 2013 Jun;58(6):339-45. doi: 10.1038/jhg.2013.41. Epub 2013 May 23. [PubMed:23697979 ]
  3. Furlong MT, Savant I, Yuan M, Scott L, Mylott W, Mariannino T, Kadiyala P, Roongta V, Arnold ME: A validated HPLC-MS/MS assay for quantifying unstable pharmacologically active metabolites of clopidogrel in human plasma: application to a clinical pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 May 1;926:36-41. doi: 10.1016/j.jchromb.2013.02.031. Epub 2013 Mar 1. [PubMed:23542721 ]
External Links
ATC CodesB01AC04
AHFS Codes
  • 20:12.18
PDB EntriesNot Available
FDA labelDownload (402 KB)
MSDSDownload (57.4 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9847
Caco-2 permeable+0.5777
P-glycoprotein substrateSubstrate0.6664
P-glycoprotein inhibitor IInhibitor0.6556
P-glycoprotein inhibitor IIInhibitor0.5558
Renal organic cation transporterInhibitor0.6368
CYP450 2C9 substrateNon-substrate0.7407
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6339
CYP450 1A2 substrateInhibitor0.724
CYP450 2C9 inhibitorNon-inhibitor0.5223
CYP450 2D6 inhibitorInhibitor0.5712
CYP450 2C19 inhibitorInhibitor0.8071
CYP450 3A4 inhibitorNon-inhibitor0.7389
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9188
Ames testNon AMES toxic0.7112
CarcinogenicityNon-carcinogens0.9597
BiodegradationNot ready biodegradable0.9911
Rat acute toxicity2.4887 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7548
hERG inhibition (predictor II)Non-inhibitor0.6329
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Dr reddys laboratories inc
  • Sanofi aventis us llc
Packagers
Dosage forms
FormRouteStrength
TabletOral300 mg/1
Tablet, film coatedOral300 mg/1
Tablet, film coatedOral75 mg/1
Tablet, film coatedOral75 mg
TabletOral75 mg/1
Tablet, film coatedOral300 mg
Tablet, film coatedOral
TabletOral300 mg
TabletOral75 mg
Prices
Unit descriptionCostUnit
Plavix 300 mg tablet24.86USD tablet
Plavix 75 mg tablet9.23USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1336777 No1995-08-222012-08-22Canada
CA2334870 No2005-03-152019-06-10Canada
US4847265 No1994-11-172011-11-17Us
US6429210 Yes1999-12-102019-12-10Us
US6504030 Yes1999-12-102019-12-10Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point158 °CNot Available
water solubility50.78 mg/LNot Available
logP2.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0118 mg/mLALOGPS
logP3.84ALOGPS
logP4.03ChemAxon
logS-4.4ALOGPS
pKa (Strongest Basic)5.14ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area29.54 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity84.93 m3·mol-1ChemAxon
Polarizability33.19 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (71.9 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alpha amino acid esters. These are ester derivatives of alpha amino acids.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentAlpha amino acid esters
Alternative Parents
Substituents
  • Alpha-amino acid ester
  • Phenylacetate
  • Thienopyridine
  • Aralkylamine
  • Halobenzene
  • Chlorobenzene
  • Benzenoid
  • Pyridine
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Methyl ester
  • Thiophene
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid ester
  • Azacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
Receptor for ADP and ATP coupled to G-proteins that inhibit the adenylyl cyclase second messenger system. Not activated by UDP and UTP. Required for normal platelet aggregation and blood coagulation.
Gene Name:
P2RY12
Uniprot ID:
Q9H244
Molecular Weight:
39438.355 Da
References
  1. Dorsam RT, Murugappan S, Ding Z, Kunapuli SP: Clopidogrel: interactions with the P2Y12 receptor and clinical relevance. Hematology. 2003 Dec;8(6):359-65. [PubMed:14668029 ]
  2. Herbert JM, Savi P: P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med. 2003 May;3(2):113-22. [PubMed:15199474 ]
  3. Taubert D, Kastrati A, Harlfinger S, Gorchakova O, Lazar A, von Beckerath N, Schomig A, Schomig E: Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost. 2004 Aug;92(2):311-6. [PubMed:15269827 ]
  4. Wang L, Jacobsen SE, Bengtsson A, Erlinge D: P2 receptor mRNA expression profiles in human lymphocytes, monocytes and CD34+ stem and progenitor cells. BMC Immunol. 2004 Aug 3;5:16. [PubMed:15291969 ]
  5. Wihlborg AK, Wang L, Braun OO, Eyjolfsson A, Gustafsson R, Gudbjartsson T, Erlinge D: ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arterioscler Thromb Vasc Biol. 2004 Oct;24(10):1810-5. Epub 2004 Aug 12. [PubMed:15308557 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Gladding P, Webster M, Zeng I, Farrell H, Stewart J, Ruygrok P, Ormiston J, El-Jack S, Armstrong G, Kay P, Scott D, Gunes A, Dahl ML: The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc Interv. 2008 Dec;1(6):620-7. doi: 10.1016/j.jcin.2008.09.008. [PubMed:19463375 ]
  8. Savi P, Zachayus JL, Delesque-Touchard N, Labouret C, Herve C, Uzabiaga MF, Pereillo JM, Culouscou JM, Bono F, Ferrara P, Herbert JM: The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):11069-74. Epub 2006 Jul 11. [PubMed:16835302 ]
  9. van Gestel MA, Heemskerk JW, Slaaf DW, Heijnen VV, Reneman RS, oude Egbrink MG: In vivo blockade of platelet ADP receptor P2Y12 reduces embolus and thrombus formation but not thrombus stability. Arterioscler Thromb Vasc Biol. 2003 Mar 1;23(3):518-23. Epub 2003 Jan 23. [PubMed:12615691 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Saw J, Steinhubl SR, Berger PB, Kereiakes DJ, Serebruany VL, Brennan D, Topol EJ: Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation. 2003 Aug 26;108(8):921-4. Epub 2003 Aug 18. [PubMed:12925453 ]
  3. Neubauer H, Gunesdogan B, Hanefeld C, Spiecker M, Mugge A: Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function--a flow cytometry study. Eur Heart J. 2003 Oct;24(19):1744-9. [PubMed:14522569 ]
  4. Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DG, Guyer KE, Tait AR, Bates ER: Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. 2004 Jan 20;109(2):166-71. Epub 2004 Jan 5. [PubMed:14707025 ]
  5. Mukherjee D, Kline-Rogers E, Fang J, Munir K, Eagle KA: Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome. Heart. 2005 Jan;91(1):23-6. [PubMed:15604326 ]
  6. Poulsen TS, Vinholt P, Mickley H, Korsholm L, Kristensen SR, Damkier P: Existence of a clinically relevant interaction between clopidogrel and HMG-CoA reductase inhibitors? Re-evaluating the evidence. Basic Clin Pharmacol Toxicol. 2005 Feb;96(2):103-10. [PubMed:15679472 ]
  7. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  8. Clarke TA, Waskell LA: The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos. 2003 Jan;31(1):53-9. [PubMed:12485953 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Walsky RL, Astuccio AV, Obach RS: Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J Clin Pharmacol. 2006 Dec;46(12):1426-38. [PubMed:17101742 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Triglyceride lipase activity
Specific Function:
Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acyl-CoA ester. Hydrolyzes the methyl ester group of cocaine to form benzoylecgonine. Catalyzes the transesterification of cocaine to form cocaethylene. Displays fatty acid ethyl ester synthase activity,...
Gene Name:
CES1
Uniprot ID:
P23141
Molecular Weight:
62520.62 Da
References
  1. Zhu HJ, Wang X, Gawronski BE, Brinda BJ, Angiolillo DJ, Markowitz JS: Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation. J Pharmacol Exp Ther. 2013 Mar;344(3):665-72. doi: 10.1124/jpet.112.201640. Epub 2012 Dec 28. [PubMed:23275066 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Taubert D, von Beckerath N, Grimberg G, Lazar A, Jung N, Goeser T, Kastrati A, Schomig A, Schomig E: Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006 Nov;80(5):486-501. [PubMed:17112805 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 07, 2016 03:54